Aoxing Pharmaceutical Company Appoints BDO China Dahua as Its Independent Auditor

Aoxing Pharmaceutical Company, Inc. /quotes/zigman/620050/quotes/nls/axn AXN 0.00% ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced the appointment of BDO China Dahua as its independent auditor. The appointment of BDO China Dahua as independent registered accounting firm has been approved by the Audit Committee of Aoxing Pharma's Board of Directors. Aoxing Pharma wishes to thank Paritz & Company, P.A. for its service as independent auditor over the years. About Aoxing Pharmaceutical Company, Inc. Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, and Phoenix PharmaLabs, Inc.

Aoxing Pharmaceutical Company Receives Special Funding From Shijiazhuang, China

Aoxing Pharmaceutical ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced Shijiazhuang City in China has granted Aoxing Pharma a special funding in the amount of $73,684 (490,000 RMB). This grant will assist in the interest payments on the company's existing bank loans.

Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented, "We continue to appreciate the support from our local government here in China, based on our accomplishments to date, enabling us to further our growth and success. We already restructured our bank loans earlier this year at more attractive rates and this grant provides additional capital savings to our shareholders. We look forward to a very exciting 2011, with additional product launches planned and the initiation of manufacturing through our joint-venture with Macfarlan Smith, a subsidiary of Johnson Matthey."

Aoxing Pharmaceutical Company Receives Manufacturing License for Joint Venture With Macfarlan Smith Ltd

Aoxing Pharmaceutical a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced the China State Food and Drug Administration (SFDA) granted a Manufacturing License to Hebei Aoxing API Pharmaceutical Company, Ltd., the joint venture between Aoxing Pharma and Macfarlan Smith Ltd, a wholly owned subsidiary of Johnson Matthey Plc.

With the Manufacturing License granted, Hebei Aoxing API Pharmaceucitcal Company submitted Business License application, to manufacture Naloxone Hydrochloride API product, to the China Administrative Bureau of Industry and Commerce.

Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented, "We are pleased to have received notice granting us a Manufacturing License from the SFDA and remain on target to begin producing API for the Chinese market in 2011. The synergies from the venture with Macfarlan Smith continue to be promising. We are excited to further the development process and to help address the need in accessing the appropriate quality and quantity of API for the finished dosage narcotics in China."

Recently Aoxing Phjarma's chemical synthesis laboratories and pilot-manufacturing plant passed GMP inspection.

Aoxing Pharmaceutical Company Announces First Quarter 2011 Financial and Operational Results

Aoxing Pharmaceutical a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced financial and operational results for the three month period ended September 30, 2010, or the first quarter of fiscal year 2011.

Aoxing Pharmaceutical Company Receives Clinical Trial Approval for Buprenorphine/Naloxone Sublingual Tablets for Opioid Addiction Treatment

Aoxing Pharmaceutical Company, Inc. /quotes/comstock/14*!axn/quotes/nls/axn (AXN 2.33, -0.05, -2.10%) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the China SFDA has granted approval of the company's New Drug Application to initiate the registration clinical trial of Buprenorphine/Naloxone sublingual tablets for opioid addiction treatment. The approval enables Aoxing Pharma to move forward to the final development stage with this therapy, which is novel in China as it is not yet available to patients.

The registration trial will be administered by the National Institute on Drug Dependence of China at Beijing University, the co-development partner of Aoxing Pharma. The patient enrollment will take place in at least three Compulsory Drug Dependence Treatment Centers. The trial is designed to establish the safety and efficacy of the Buprenorphine/Naloxone sublingual tablet therapy among patients who are suffering from opioid dependence.